Authors
Latest:
Optimizing Treatment Decisions for Patients With CMLMichael J. Mauro, MD, discusses decision-making for patients with chronic myeloid leukemia.
Latest:
Results of the ECOG E3805 StudyMichael J. Morris, MD, GU Oncologists, Memorial Sloan Kettering Cancer Center, discusses the results of the ECOG E3805 study, which examined chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer.
Latest:
Targeted Radioligand Therapy Shows Efficacy in PSMA-Positive mCRPCMichael J. Morris, MD, discusses the results of the VISION trial of 177-lutetium-PSMA-61 in patients with metastatic castration-resistant prostate cancer.
Latest:
Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal CancersIn season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer
Latest:
Dr. Michael Lim on Toxicities of Checkpoint Inhibitors in GlioblastomaMichael Lim, MD, director of Brain Tumor Immunotherapy, associate professor of Neurosurgery, Johns Hopkins Medicine, discusses checkpoint inhibitors in glioblastoma.
Latest:
Dr. Michael Manns on a Possible Link Between Hepatitis C and Hepatocellular CarcinomaMichael Manns, MD, explains the possible link between hepatitis C and hepatocellular carcinoma.
Latest:
Dr. Michael Mauro on Toxicities of TKI Usage in Patients With CMLMichael Mauro, MD, discusses the side effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Latest:
Novel Hepatitis C Treatments Impact HCC Care: Q&A With Michael P. Manns, MDNovel agents that target the replication of the hepatitis C virus are poised to have a far-reaching impact on the prevention and recurrence of hepatocellular carcinoma (HCC).
Latest:
Genetic Testing Should Be Considered for All Patients With Pancreatic CancerMichael J. Pishvaian, MD, PhD, discusses the key takeaway from his presentation at the 17th Annual Meeting of the International Society of Gastrointestinal Oncology on the role of genetic testing in patients with pancreatic cancer.
Latest:
LEGACY Trial of Radioembolization Shows Practice-Changing Data in HCCMichael R. Charlton, MD, MBBS, discusses the impact of the LEGACY trial investigating yttrium-90 radioembolization in patients with solitary, unresectable hepatocellular carcinoma.
Latest:
Case Shows Dramatic Antitumor Effects With Immunotherapy in MelanomaA letter to the editor in the New England Journal of Medicine from notable researchers at Memorial Sloan Kettering reported a case of complete remission of metastatic melanoma in a patient treated with single doses of ipiliumab and nivolumab.
Latest:
Lean Body Mass as a Clinical Outcome in Multicentric Castleman’s DiseaseMichael Sawyer, MD, associate professor, Medical Oncology, University of Alberta, discusses lean body mass as a clinical outcome in multicentric Castleman’s disease.
Latest:
Dr. Michael Tuttle on Dosimetry Versus Empiric Dosing Radioactive Iodine TreatmentMichael Tuttle, MD, endocrinologist Memorial Sloan Kettering (MSK), discusses best management approaches to radioactive iodine treatment in patients with radioiodine avid distant metastases from differentiated thyroid cancer.
Latest:
Patients Resistant to Covalent BTK Inhibitors Remain a Challenge in MCLMichael Wang, MD, discusses where unmet needs still exist for patients with relapsed/refractory mantle cell lymphoma.
Latest:
Treatment Strategies to Optimize Outcomes With Brentuximab Vedotin: Management of Common and Rare ToxicitiesCommon AEs associated with brentuximab vedotin, such as peripheral neuropathy and neutropenia, are often manageable with modifications to dose and schedule.
Latest:
Patient Selection for Newly Approved Agents in T-Cell LymphomaMichelle Fanale, MD, associate professor, University of Texas MD Anderson Cancer Center, discusses patient selection for newly approved agents in T-cell lymphoma.
Latest:
REACH-2: Ruxolitinib Is Viable Option in Steroid-Refractory Acute GVHDExperts decide whether ruxolitinib is a viable treatment option for steroid-refractory acute graft-versus-host-disease based on the case of a 48-year-old patient.
Latest:
An Overview of the PROGRESS II Trial in Acute Leukemia and Myelodysplastic SyndromeMiguel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, and director, Adult Bone Marrow Transplantation Fellowship Program, gives an overview of the PROGRESS II trial in acute leukemia and myelodysplastic syndrome during the ASH Annual Meeting.
Latest:
Markers of ExcellenceThe word "marker" is defined, in medical terms, as "something that serves to identify, predict, or characterize." A variation on this word, known as a biological marker, or biomarker (defined as a measurable indicator of a biological condition) takes this concept one step further.
Latest:
Questions Linger Around COVID-19’s OriginDebate and discussion about the origin of the virus that causes COVID-19 have been at the forefront of the global consciousness since the first cases were reported in December 2019.
Latest:
Oncologists' Use of Twitter at ConferencesMike Thompson, MD, PhD, from Stillwaters Cancer Support Services, discusses oncologists’ use of and attitudes towards Twitter.
Latest:
Factors Associated With Discordance in Mutation Status in Metastatic CRCMikhail Fedyanin, MD, medical oncologist, Russian Academy of Medical Sciences, Moscow, discusses some of the factors associated with discordance in mutation status in metastatic colorectal cancer during the 2016 ESMO Congress.
Latest:
Expert Panel Discusses the Financial and Economic Impact of BiosimilarsDuring a preconference presentation at the Association of Community Cancer Centers 35th National Oncology Conference in Phoenix, a panel of experts discussed the challenges they foresee with the wave of new biosimilar launches expected in 2019.
Latest:
The Limitations of Radiology in Metastatic Breast CancerMinetta Liu, MD, discusses the limitations of radiology in the treatment of patients with metastatic breast cancer.
Latest:
PARP Inhibitors Advance Beyond Treatment of BRCA1/2-Mutant Gynecologic CancersMira Hellmann, MD, discusses how the use of PARP inhibitors as treatment of patients with gynecologic cancers has evolved since they were first introduced into the treatment landscape up to studies evaluating these therapies today in a variety of patient populations, particularly in patients with ovarian cancer.
Latest:
How Physical Activity, Obesity and Smoking Impact Bladder Cancer MortalityMoben Mirza, MD, assistant professor of urology at the University of Kansas Medical Center, discusses a study that examines the impact of physical activity, obesity, and smoking on bladder cancer mortality.
